Regencell Bioscience Holdings Ltd
RGC11.280USD
-0.400-3.42%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
5.58BMarket Cap
--P/E TTM
More Details of Regencell Bioscience Holdings Ltd Company
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Regencell Bioscience Holdings Ltd Info
Ticker SymbolRGC
Company nameRegencell Bioscience Holdings Ltd
IPO dateJul 16, 2021
CEO- -
Number of employees12
Security typeOrdinary Share
Fiscal year-endJul 16
Address11/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay
City
Stock exchangeNASDAQ Capital Market Consolidated
CountryHong Kong
Postal code- -
Phone85221550823
Websitehttps://www.regencellbioscience.com/
Ticker SymbolRGC
IPO dateJul 16, 2021
CEO- -
Company Executives of Regencell Bioscience Holdings Ltd
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Au (Yat-Gai)
88.56%
Geode Capital Management, L.L.C.
0.08%
Squarepoint Capital LLP
0.01%
Other
11.35%
Shareholders
Shareholders
Proportion
Au (Yat-Gai)
88.56%
Geode Capital Management, L.L.C.
0.08%
Squarepoint Capital LLP
0.01%
Other
11.35%
Shareholder Types
Shareholders
Proportion
Individual Investor
88.56%
Investment Advisor/Hedge Fund
0.10%
Research Firm
0.01%
Other
11.34%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
21
671.84K
0.14%
+311.14K
2025Q2
15
464.50M
93.94%
+23.83M
2025Q1
12
464.34M
93.90%
+23.68M
2024Q4
10
11.60M
89.11%
+20.25K
2024Q3
10
11.58M
89.01%
+24.37K
2024Q2
11
11.57M
88.87%
+5.63K
2024Q1
12
11.56M
88.83%
-17.42K
2023Q4
12
11.57M
88.94%
+13.30K
2023Q3
13
11.56M
88.82%
-12.42K
2023Q2
13
11.55M
88.77%
-36.88K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Au (Yat-Gai)
437.90M
88.56%
+11.47M
+2.69%
Jul 11, 2025
Geode Capital Management, L.L.C.
391.07K
0.08%
+132.06K
+50.99%
Jun 30, 2025
Squarepoint Capital LLP
99.84K
0.02%
+99.84K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
32.42K
0.01%
+32.23K
+16965.79%
Jun 30, 2025
BlackRock Financial Management, Inc.
4.87K
0%
-4.18K
-46.21%
Jun 30, 2025
BNP Paribas Securities Corp. North America
45.05K
0.01%
+45.05K
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Fidelity Nasdaq Composite Index ETF
0.02%
SPDR S&P China ETF
0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.02%
SPDR S&P China ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Regencell Bioscience Holdings Ltd?
The top five shareholders of Regencell Bioscience Holdings Ltd are:
Au (Yat-Gai) holds 437.90M shares, accounting for 88.56% of the total shares.
Geode Capital Management, L.L.C. holds 391.07K shares, accounting for 0.08% of the total shares.
Squarepoint Capital LLP holds 99.84K shares, accounting for 0.02% of the total shares.
Morgan Stanley & Co. LLC holds 32.42K shares, accounting for 0.01% of the total shares.
BlackRock Financial Management, Inc. holds 4.87K shares, accounting for 0.00% of the total shares.
Au (Yat-Gai) holds 437.90M shares, accounting for 88.56% of the total shares.
Geode Capital Management, L.L.C. holds 391.07K shares, accounting for 0.08% of the total shares.
Squarepoint Capital LLP holds 99.84K shares, accounting for 0.02% of the total shares.
Morgan Stanley & Co. LLC holds 32.42K shares, accounting for 0.01% of the total shares.
BlackRock Financial Management, Inc. holds 4.87K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Regencell Bioscience Holdings Ltd?
The top three shareholder types of Regencell Bioscience Holdings Ltd are:
Au (Yat-Gai)
Geode Capital Management, L.L.C.
Squarepoint Capital LLP
Au (Yat-Gai)
Geode Capital Management, L.L.C.
Squarepoint Capital LLP
How many institutions hold shares of Regencell Bioscience Holdings Ltd (RGC)?
As of 2025Q3, 21 institutions hold shares of Regencell Bioscience Holdings Ltd, with a combined market value of approximately 671.84K, accounting for 0.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -93.80%.
What is the biggest source of revenue for Regencell Bioscience Holdings Ltd?
In --, the -- business generated the highest revenue for Regencell Bioscience Holdings Ltd, amounting to -- and accounting for --% of total revenue.
